华熙生物
(688363)
| 流通市值：121.88亿 | | | 总市值：296.23亿 |
| 流通股本：1.98亿 | | | 总股本：4.82亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,360,531,915 | 6,075,923,853.74 | 4,221,434,960.6 | 3,075,611,629.22 |
| 营业收入 | 1,360,531,915 | 6,075,923,853.74 | 4,221,434,960.6 | 3,075,611,629.22 |
| 二、营业总成本 | 1,042,739,955.34 | 5,438,234,078.17 | 3,695,744,556.37 | 2,625,933,511.09 |
| 营业成本 | 330,181,652.26 | 1,621,027,890.22 | 1,136,684,136.32 | 805,884,531.69 |
| 税金及附加 | 15,043,523.89 | 67,100,887.26 | 44,759,884.7 | 29,980,036.53 |
| 销售费用 | 490,355,142.58 | 2,842,387,206.28 | 1,942,502,310.2 | 1,420,217,921.56 |
| 管理费用 | 116,094,685.69 | 492,166,284.58 | 319,679,745.44 | 205,484,635.42 |
| 研发费用 | 95,741,342.1 | 446,346,769.17 | 277,108,880.65 | 186,700,314.21 |
| 财务费用 | -4,676,391.18 | -30,794,959.34 | -24,990,400.94 | -22,333,928.32 |
| 其中:利息费用 | 1,290,729.41 | 6,230,423.38 | 5,126,353.43 | 5,962,311.64 |
| 其中:利息收入 | 5,985,622.41 | 38,456,118.58 | 29,597,021.94 | 21,346,576.52 |
| 加:公允价值变动收益 | - | 1,467,665.76 | 236,066.67 | 260,750 |
| 加:投资收益 | -1,591,342.57 | 1,327,375.89 | 1,853,827.64 | 1,597,280.23 |
| 资产处置收益 | - | -3,424,302.25 | - | - |
| 资产减值损失(新) | -7,135,537.86 | -54,403,392.42 | -3,813,026.38 | -210,691.87 |
| 信用减值损失(新) | -22,948,505.65 | -5,063,483.4 | -11,355,516.33 | -10,158,885.5 |
| 其他收益 | 14,202,539.34 | 130,791,911.44 | 98,552,951.44 | 76,443,319.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 300,319,112.92 | 708,385,550.59 | 611,164,707.27 | 517,609,890.03 |
| 加:营业外收入 | 545,158.16 | 2,865,147.21 | 1,964,100.96 | 1,680,177.24 |
| 减:营业外支出 | 259,602.73 | 9,528,235.16 | 2,701,348.63 | 2,660,056.11 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 300,604,668.35 | 701,722,462.64 | 610,427,459.6 | 516,630,011.16 |
| 减:所得税费用 | 57,217,016.03 | 118,980,429.13 | 103,344,481.68 | 95,068,103.83 |
| 六、净利润 | 243,387,652.32 | 582,742,033.51 | 507,082,977.92 | 421,561,907.33 |
| 持续经营净利润 | 243,387,652.32 | 582,742,033.51 | 507,082,977.92 | 421,561,907.33 |
| 归属于母公司股东的净利润 | 243,367,321.4 | 592,555,911.37 | 514,400,873.54 | 424,608,695.6 |
| 少数股东损益 | 20,330.92 | -9,813,877.86 | -7,317,895.62 | -3,046,788.27 |
| (一)基本每股收益 | 0.51 | 1.23 | 1.07 | 0.88 |
| (二)稀释每股收益 | 0.51 | 1.23 | 1.07 | 0.88 |
| 八、其他综合收益 | -9,119,542.06 | 28,665,320.95 | 7,791,296.79 | 20,336,182.59 |
| 归属于母公司股东的其他综合收益 | -9,119,542.06 | 28,665,320.95 | 7,791,296.79 | 20,336,182.59 |
| 九、综合收益总额 | 234,268,110.26 | 611,407,354.46 | 514,874,274.71 | 441,898,089.92 |
| 归属于母公司股东的综合收益总额 | 234,247,779.34 | 621,221,232.32 | 522,192,170.33 | 444,944,878.19 |
| 归属于少数股东的综合收益总额 | 20,330.92 | -9,813,877.86 | -7,317,895.62 | -3,046,788.27 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |